NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $8.71 0.00 (0.00%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$8.71 0.00 (0.00%) As of 04/23/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Entrada Therapeutics Stock (NASDAQ:TRDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$8.69▼$9.2350-Day Range$7.55▼$13.4452-Week Range$7.10▼$21.79Volume155,926 shsAverage Volume124,588 shsMarket Capitalization$327.45 millionP/E Ratio5.48Dividend YieldN/APrice Target$25.67Consensus RatingBuy Company OverviewEntrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More… Entrada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 528th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from $1.12 to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is 5.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is 5.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.97.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.32% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 4.88%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.32% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 4.88%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News SentimentN/A News SentimentEntrada Therapeutics has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Entrada Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for TRDA on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.59% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Stock News HeadlinesEntrada Therapeutics Receives UK Approval To Start Phase 1/2 Trial Of ENTR-601-45 For DMDMarch 26, 2025 | nasdaq.comEntrada receives authorization in the UK to initiate ELEVATE-45-201 studyMarch 25, 2025 | markets.businessinsider.comVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.April 24, 2025 | Stansberry Research (Ad)Entrada Therapeutics gets approval to start trial of its DMD treatment in the UKMarch 24, 2025 | msn.comEntrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMarch 24, 2025 | globenewswire.comEntrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen NextMarch 3, 2025 | finance.yahoo.comEntrada Therapeutics price target lowered to $23 from $29 at Roth MKMMarch 1, 2025 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)February 28, 2025 | markets.businessinsider.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $17.29 on January 1st, 2025. Since then, TRDA shares have decreased by 49.6% and is now trading at $8.71. View the best growth stocks for 2025 here. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings results on Thursday, February, 27th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.69. The firm earned $12.25 million during the quarter, compared to analysts' expectations of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a trailing twelve-month return on equity of 16.11%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Top institutional investors of Entrada Therapeutics include Harbor Capital Advisors Inc. (0.04%). Insiders that own company stock include Bros Advisors Lp Baker, Bioventures 2018 LP Mpm, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth, Peter S Kim and Nerissa Kreher. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings2/27/2025Today4/24/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRDA CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$25.67 High Stock Price Target$29.00 Low Stock Price Target$20.00 Potential Upside/Downside+194.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.91 Trailing P/E Ratio5.48 Forward P/E Ratio7.78 P/E GrowthN/ANet Income$-6,680,000.00 Net Margins25.53% Pretax Margin35.51% Return on Equity16.11% Return on Assets10.39% Debt Debt-to-Equity RatioN/A Current Ratio6.59 Quick Ratio6.59 Sales & Book Value Annual Sales$210.78 million Price / Sales1.55 Cash FlowN/A Price / Cash FlowN/A Book Value$7.26 per share Price / Book1.20Miscellaneous Outstanding Shares37,595,000Free Float34,580,000Market Cap$327.45 million OptionableOptionable Beta0.04 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:TRDA) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.